Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Cisplatin + Nab-paclitaxel in Resectable HNSCC
NCT04826679Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2021
- Primary completion
- Apr 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Sun Yat-sen University. Primary endpoint: Objective Response Rate at 9 weeks. Started Apr 2021; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04826679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04826679.